{
    "clinical_study": {
        "@rank": "89052", 
        "arm_group": [
            {
                "arm_group_label": "capecitabine", 
                "arm_group_type": "Experimental", 
                "description": "capecitabine 1250 milligram (mg) / m\u00b2 po bid (D1-14)"
            }, 
            {
                "arm_group_label": "observation", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "single center, prospective, randomized, open-label phase III"
        }, 
        "brief_title": "Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer", 
        "completion_date": {
            "#text": "September 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, randomized, open-label phase III study of adjuvant chemotherapy after\n      curative resection in patients with pathologic stage IB (by AJCC 6th edition) gastric cancer\n      with at least one additional risk factor (additional risk factors for recurrence include age\n      >65 years, male gender, presence of lymphovascular invasion, presence of perineural\n      invasion, and elevation of CEA or CA19-9). The superiority design will compare the efficacy\n      and safety profiles of adjuvant capecitabine (Arm A) versus observation alone (Arm B)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Curatively resected gastric or gastroesophageal junction adenocarcinoma\n\n          -  Pathologic stage IB (by AJCC 6th edition) with at least one additional risk factor\n             for recurrence (additional risk factors for recurrence include age >65 years, male\n             gender, presence of lymphovascular invasion, presence of perineural invasion).\n\n          -  Age: 18 -74years\n\n          -  ECOG performance status: 0-2\n\n          -  Adequate bone marrow function (ANC >1,500/uL, Platelets 100,000/uL, and Hb > 8.0\n             g/dL)\n\n          -  Adequate renal function (serum creatinine < 1.5 mg/dL)\n\n          -  Adequate hepatic function (bilirubin < 1.5 mg/dL, ALT and AST < 3 times upper limit\n             of normal)\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women.\n\n          -  Women of childbearing potential with either a positive pregnancy test at baseline.\n             Postmenopausal women must have been amenorrheic for at least 12 months to be\n             considered of non-child bearing potential.\n\n          -  Sexually active males and females (of childbearing potential) unwilling to practice\n             contraception during the study medication and until 3 months after discontinuation of\n             the study medication.\n\n          -  Any evidence of metastatic disease (including presence of tumor cells in the\n             ascites).\n\n          -  Previous chemotherapy or radiotherapy for the currently treated gastric cancer.\n\n          -  No recovery from serious complications of gastrectomy.\n\n          -  History of another malignancy within the last five years except cured basal cell\n             carcinoma of skin and cured carcinoma in-situ of uterine cervix.\n\n          -  History of uncontrolled seizures, central nervous system disorders or psychiatric\n             disability judged by the investigator to be clinically significant precluding\n             informed consent or interfering with compliance for oral drug intake.\n\n          -  Clinically significant (i.e. active) cardiac disease: e.g. unstable angina,\n             symptomatic coronary artery disease, New York Heart Association (NYHA) grade II or\n             greater congestive heart failure or serious cardiac arrhythmia requiring medication\n             or myocardial infarction within the last 6 months.\n\n          -  Lack of physical integrity of the upper gastrointestinal tract or those who have\n             malabsorption syndrome likely to influence absorption of capecitabine, or inability\n             to take oral medication.\n\n          -  Serious uncontrolled intercurrent infections or other serious uncontrolled\n             concomitant disease.\n\n          -  Organ allografts requiring immunosuppressive therapy.\n\n          -  Received any investigational drug or agent/procedure, i.e. participation in another\n             trial within 4 weeks before randomization.\n\n          -  Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or\n             chemically related analogues, such as brivudine.\n\n          -  Positive serologic test for HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "870", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917552", 
            "org_study_id": "AMC1301"
        }, 
        "intervention": {
            "arm_group_label": "capecitabine", 
            "description": "capecitabine 1250 milligram (mg) / m\u00b2 po bid (D1-14)", 
            "intervention_name": "capecitabine", 
            "intervention_type": "Drug", 
            "other_name": "Xeloda"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, adjuvant, capecitabine, gastric cancer, stage 1b", 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "contact": {
                "email": "ykkang@amc.seoul.kr", 
                "last_name": "Kang Yoon-Koo, MD, PhD", 
                "phone": "82-2-3010-3230"
            }, 
            "contact_backup": {
                "email": "miniryu@amc.seoul.kr", 
                "last_name": "Ryu Min-Hee, MD, PhD", 
                "phone": "82-2-3010-5935"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Songpa-gu", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Kang Yoon-Koo, MD,PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ryoo Back-Yeol, MD,PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ryu Min-Hee, MD,PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Park Sook-Ryun, MD,PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nam Byung-Ho", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kim Byung-Sik", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yook Jeong-Hwan, MD,PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yoo Moon-Won", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kim Bum-Soo", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer", 
        "overall_contact": {
            "email": "ykkang@amc.seoul.kr", 
            "last_name": "Kang Yoon-Koo, MD, PhD", 
            "phone": "82-2-3010-3230"
        }, 
        "overall_contact_backup": {
            "email": "miniryu@amc.seoul.kr", 
            "last_name": "Ryu Min-Hee, MD, PhD", 
            "phone": "82-2-3010-5935"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Kang Yoon-Koo, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "South Korea: Institutional Review Board", 
                "South Korea: Ministry of Food and Drug Safety (MFDS)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To demonstrate that capecitabine is superior to observation only (control arm) in terms of recurrence-free survival in curatively resected stage IB gastric cancer.", 
            "measure": "recurrence-free survival", 
            "safety_issue": "No", 
            "time_frame": "8 years"
        }, 
        "reference": [
            {
                "PMID": "16145066", 
                "citation": "Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005 Oct 1;23(28):6957-65. Epub 2005 Sep 6."
            }, 
            {
                "PMID": "22226517", 
                "citation": "Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirz\u00e9n F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7."
            }, 
            {
                "PMID": "9690942", 
                "citation": "Diasio RB. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol. 1998 Jul;46(1):1-4."
            }, 
            {
                "PMID": "10600095", 
                "citation": "Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH. Warfarin-5-FU interaction--a consecutive case series. Pharmacotherapy. 1999 Dec;19(12):1445-9."
            }, 
            {
                "PMID": "18665164", 
                "citation": "Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer. 2008 Aug 19;99(4):584-90. Epub 2008 Jul 29."
            }, 
            {
                "PMID": "9440756", 
                "citation": "O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998 Jan;16(1):295-300."
            }, 
            {
                "PMID": "17978289", 
                "citation": "Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20."
            }, 
            {
                "citation": "Sasako M, Sakuramoto S, Katai H et al. (2011). Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol, 29, 4387-4393"
            }, 
            {
                "PMID": "1579757", 
                "citation": "Lakatos E, Lan KK. A comparison of sample size methods for the logrank statistic. Stat Med. 1992 Jan 30;11(2):179-91."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917552"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Yoon-Koo Kang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare overall survival in the capecitabine arm compared with the control arm.", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "8 years"
            }, 
            {
                "description": "Toxicity profiles will be assessed with the patient 28 +/- 3 days after the last intake of study medication is required. (treatment arm only)", 
                "measure": "Safety profiles", 
                "safety_issue": "Yes", 
                "time_frame": "8years"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}